Consensus document. Recommendations on assessing proteinuria during the diagnosis and follow-up of chronic kidney disease.

The presence of persistently elevated urinary concentrations of protein or albumin is considered a sign of kidney damage. The diagnosis and staging of chronic kidney disease (CKD) is nowadays based upon the presence of signs of kidney damage together with the estimation of the glomerular filtration rate.The presence of either proteinuria or albuminuria identifies a group of patients with higher risk of CKD progression and higher cardiovascular risk. Treatment with angiotensin converting enzyme inhibitors or angiotensin-receptor blockers,for instance, decreases both the progression of CKD and the incidence of cardiovascular events and death in patients with CKD and proteinuria. Thus, proteinuria is currently considered a therapeutic target by itself. Despite of the importance of detecting and monitoring proteinuria in the diagnosis and follow-up of CKD, there is not a consensus among the clinical practice guidelines published by different scientific societies on the diagnostic cut-off levels, on different sampling procedures,on the units used in laboratory reports or just on whether it should be defined in terms of albumin or proteinuria. The goal of this document, created by the consensus of the Spanish Society of Clinical Biochemistry and Molecular Pathology(SEQC, representing its spanish acronym) and the Spanish Society of Nephrology (S.E.N.), is to recommend to medical and laboratory clinicians appropriate guidelines for the detection and monitorization of proteinuria as a marker of CKD in adults and children. These recommendations result from searching,evaluating and summarizing current scientific evidence published in the last years.

Documento de Consenso. Recomendaciones sobre la valoración de la proteinuria en el diagnóstico y seguimiento de la enfermedad renal crónica / Consensus Document. Recommendations on assessing proteinuria during the diagnosis and follow-up of chronic kidney disease

La presencia de concentraciones elevadas de proteína o albúmina en orina, de modo persistente, es un signo de lesión renal y constituye, junto con la estimación del filtrado glomerular, la base sobre la que se sustenta el diagnóstico de la enfermedad renal crónica (ERC). Su presencia identifica a un grupo de pacientes con un riesgo superior de progresión de la enfermedad renal y con mayor morbilidad cardiovascular. El tratamiento con inhibidores de la enzima de conversión de la angiotensina o antagonistas del receptor de la angiotensina, en individuos con ERC y proteinuria, ha demostrado que disminuye tanto la progresión de la enfermedad renal como la incidencia de eventos cardiovasculares y muerte, por lo que la disminución del valor de la proteinuria es considerado un objetivo terapéutico. Pese a la importancia de la detección y monitorización de la proteinuria en el diagnóstico y seguimiento de la ERC, no existe consenso entre las guías de práctica clínica publicadas por distintas Sociedades científicas sobre cuáles son los valores que indican su presencia, si ésta debe ser definida en términos de albúmina o de proteína, el espécimen más adecuado para su medida o el tipo de unidades en que deben ser expresados los resultados. La finalidad de este documento, elaborado con el consenso de la Sociedad Española de Bioquímica Clínica y Patología Molecular (SEQC) y la Sociedad Española de Nefrología (S.E.N.), es proporcionar recomendaciones, a los facultativos clínicos y de laboratorio, para la detección y monitorización de la proteinuria como marcador de la presencia de ERC en adultos y en niños. Las recomendaciones son el resultado de la búsqueda, evaluación y síntesis de la evidencia científica publicada sobre el tema en los últimos años (AU)

The presence of persistently high urinary concentrations of protein or albumin is considered a sign of kidney damage. Nowadays, the diagnosis of chronic kidney disease (CKD) is based on the presence of signs of kidney damage together with the estimation of the glomerular filtration rate. The presence of either proteinuria or albuminuria identifies a group of patients with a higher risk of progression of CKD and higher cardiovascular risk. Treatment with angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers decreases both the progression of CKD and the incidence of cardiovascular events and death in patients with CKD and proteinuria. Thus, proteinuria is currently considered a therapeutic target by itself. Despite the importance of detecting and monitoring proteinuria in the diagnosis and follow-up of CKD, there is no consensus among the clinical practice guidelines published by different scientific societies on the diagnostic cut-off levels, on different sampling procedures, on the units used in laboratory reports or just on whether it should be defined in terms of albuminuria or proteinuria. The goal of this document, created with the agreement of the Spanish Society of Clinical Biochemistry and Molecular Pathology (SEQC, representing its Spanish acronym) and the Spanish Society of Nephrology (S.E.N.), is to recommend appropriate guidelines to medical and laboratory physicians for detecting and monitoring proteinuria as a marker of CKD in adults and children. These recommendations are the result of searching, evaluating and summarising current scientific evidence published in the last few years (AU)

Valoración de la nueva ecuación CKD-EPI para la estimación del filtrado glomerular / Assessment of the new CKD-EPI equation to estimating glomerular filtration rate

Introducción: Recientemente el grupo CKD-EPI (ChronicKidney Disease Epidemiology Collaboration) ha publicado una nueva ecuación de estimación del filtrado glomerular(FG) desarrollada a partir de una población de 8.254 individuosa los que se midió el FG mediante aclaramiento de iotalamato (media 68 ml/min/1,73 m2, DE 40ml/min/1,73 m2), y que incluye como variables la creatinina sérica, la edad, el sexo y la raza, con distintas versiones en función de la etnia, el sexo y el valor de la creatinina. La ecuación de CKD-EPI mejoró los resultados en cuanto a exactitud y precisión de la ecuación de elección actual MDRD-IDMS (Modification of Diet in Renal Disease-Isotopic Dilution Mass Spectrometry) en especial para valores de FG superior a 60 ml/min/1,73 m2 en un grupo de 3.896individuos. Material y métodos: El objetivo de nuestro estudio fue comparar los valores de FG estimado utilizando la nueva ecuación de CKD-EPI frente a MDRD-IDMS en una amplia cohorte de 14.427 pacientes (5.234 mujeres y 9.193hombres) y analizar las repercusiones que el uso de CKDEPI tendría a la hora de clasificar a la población en distintos estadios de enfermedad renal crónica (ERC) en función de su FG. Resultados: La media del FG estimado fue 0,6ml/min/1,73 m2 más alto por CKD-EPI que por MDRD-IDMS en el grupo total, 1,9 ml/min/1,73 m2 más alto en el grupo (..) (AU)

Introduction: A recent report by the CKD-EPI Chronic Kidney Disease Epidemiology Collaboration) group describes a new equation to estimate the glomerular filtration rate (GFR).This equation has been developed from a population of8,254 subjects who had the GFR measured by iothalamate clearance (mean 68 ml/min/1.73 m2, SD 40 ml/min/1.73 m2).It includes variables such as serum creatinine, age, sex and race with different formula according to race, sex and creatinine value. The CKD-EPI equation improved the accuracy and precision results of the current first-choice MDRDIDMS(Modification of Diet in Renal Disease-Isotopic Dilution Mass Spectrometry) formula, specially for GFR >60ml/min/1.73 m2 in a group of 3,896 subjects. Methods: The goal of our study was to compare the estimated GFR by using the new equation CKD-EPI with MDRD-IDMS in a wide cohort of 14,427 patients (5,234 women and 9,193 men),and to analyze the impact of the new CKD-EPI formula on (AU)

[Assessment of the new CKD-EPI equation to estimate the glomerular filtration rate]. / Valoración de la nueva ecuación CKD-EPI para la estimación del filtrado glomerular.

INTRODUCTION: A recent report by the CKD-EPI Chronic Kidney Disease Epidemiology Collaboration) group describes a new equation to estimate the glomerular filtration rate (GFR). This equation has been developed from a population of 8,254 subjects who had the GFR measured by iothalamate clearance (mean 68 mL/min/1.73 m2, SD 40 mL/min/1.73 m2). It includes variables such as serum creatinine, age, sex and race with different formula according to race, sex and creatinine value. The CKD-EPI equation improved the accuracy and precision results of the current first-choice MDRD-IDMS (Modification of Diet in Renal Disease-Isotopic Dilution Mass Spectrometry) formula, specially for GFR > 60 mL/min/1.73 m2 in a group of 3,896 subjects. METHODS: The goal of our study was to compare the estimated GFR by using the new equation CKD-EPI with MDRD-IDMS in a wide cohort of 14,427 patients (5,234 women and 9,193 men), and to analyze the impact of the new CKD-EPI formula on the staging of patients with CKD. RESULTS: Mean estimated GFR was 0.6 mL/min/1.73 m2 higher with CKD-EPI as compared to MDRD-IDMS for the whole group, 1.9 mL/min/1.73 m2 higher for women and 0.2 mL/min/1.73 m2 lower for men. The percentage of CKD staging concordancy between equations varied from 79.4 % for stage 3A and 98.6% for stage 5. For those patients younger than 70 years, 18.9 % and 24 % MDRD-IDMS stages 3B and 3A were reclassified as CKD 3A and 2 by CKD-EPI, respectively. For the same stages in the group younger than 70 years, the percentage of reclassified patients increased up to 34.4% and 33.4%, respectively. CONCLUSION: The new CKD-EPI equation to estimate the GFR reclassifies an important number of patients to higher CKD stages (higher GFR), specially younger women, classified as CKD stage 3 by MDRD-IDMS.